{
    "clinical_study": {
        "@rank": "18311", 
        "arm_group": [
            {
                "arm_group_label": "Acupoint  and tropisetron", 
                "arm_group_type": "Experimental", 
                "description": "acupoint electric stimulation combined with tropisetron 6mg before TACE"
            }, 
            {
                "arm_group_label": "tropisetron", 
                "arm_group_type": "Active Comparator", 
                "description": "treated with tropisetron 6mg before TACE"
            }
        ], 
        "brief_summary": {
            "textblock": "Observation on acupoint electric stimulation combined with tropisetron in preventing and\n      treating nausea and vomiting and improving the patient's appetite after TACE for primary or\n      metastatic liver cancer patients."
        }, 
        "brief_title": "Acupoint Electric Stimulation Combined With Tropisetron in Preventing and Treating Nausea and Vomiting After TACE", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Nausea", 
            "Vomiting", 
            "Metastatic Liver Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Liver Neoplasms", 
                "Nausea", 
                "Vomiting"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  Classification of nausea and vomiting, as measured by NCI CTC-AE version 3\n\n        -  The improvement of appetite, as measure by the classification of Appetite in accordance\n           with NCI CTC-AE version 3.\n\n        -  Quality of life: use M. D. Anderson symptom scale (the m. d. Anderson Symptom\n           Inventory,MDASI)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  ECOG physical status 0,1,2\n\n          -  would accept the transcatheter hepatic arterial chemoembolization of primary or\n             metastatic liver cancer patients;\n\n          -  Adult male and female 3, age 18 years old;\n\n          -  the chem-scheme of arterial infusion chemotherapy based on oxaliplatin dosage of\n             200mg;\n\n          -  signed the informed consent and understand the study design;\n\n          -  Organ function examination in patients must meet the following laboratory indexes:\n             Neutrophil>500/Ul, hemoglobin > 8 gm/dL, platelet >100000/uL,Creatinine < 2 mg/dL\n             bilirubin < 1.5 mg/dL, , alanine aminotransferase < 3 times the normal value, albumin\n             >30g/L\n\n          -  understand and complete quality of life scale ;\n\n          -  women of childbearing age urine pregnancy test was negative.\n\n        Exclusion Criteria:\n\n          -  The combined use of other venous chemotherapy within 5 days after TACE;\n\n          -  skin infection on or near the points;\n\n          -  skin hyperalgesia, unable to withstand electrical stimulation;\n\n          -  other confounding factors may cause nausea and vomiting (such as intestinal\n             obstruction, anorexia, etc.);\n\n          -  heart, cerebrovascular accident history or the history of spinal cord injury;\n\n          -  intestinal obstruction lead to nausea and vomiting\n\n          -  installing pacemaker;\n\n          -  cognitive dysfunction, unable to finish Scale;\n\n          -  currently using acupuncture therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "74", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01895010", 
            "org_study_id": "ESA2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Acupoint  and tropisetron", 
                "description": "acupoint electric stimulation combined with tropisetron 6mg before TACE", 
                "intervention_name": "acupoint electric stimulation", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "tropisetron", 
                "description": "only tropisetron 6mg before TACE", 
                "intervention_name": "tropisetron", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tropisetron"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "prevention and treatment", 
            "improvement of the patient's appetite", 
            "TACE"
        ], 
        "lastchanged_date": "July 9, 2013", 
        "location": {
            "contact": {
                "email": "zhuxiaoyan@fudan.edu.cn", 
                "last_name": "Xiaoyan Zhu, Dotral", 
                "phone": "+08602164175590", 
                "phone_ext": "3625"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Shanghai Cancer Center"
            }, 
            "investigator": {
                "last_name": "Xiaoyan Zhu, doc", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Acupoint Electric Stimulation Combined With Tropisetron in Preventing and Treating Nausea and Vomiting After TACE", 
        "overall_official": {
            "affiliation": "Shanghai Cancer Centre, Fudan University", 
            "last_name": "Xiaoyan Zhu, Doc", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Classification of nausea and vomiting", 
            "safety_issue": "No", 
            "time_frame": "12 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01895010"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "zhu xiao yan", 
            "investigator_title": "Attending doctor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "The improvement of appetite", 
            "safety_issue": "No", 
            "time_frame": "12 month"
        }, 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}